ASH 2017

Combination treatment with nivolumab plus azacitidine produced encouraging response rates in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with poor-risk features, and in elderly patients as frontline therapy.
Read Article

A phase 1 dose-escalation study of FLX925, a dual FLT3 and CDK4/6 inhibitor, showed modest antileukemic activity in adult patients with relapsed or refractory acute myeloid leukemia (AML).
Read Article

An analysis of response and survival outcomes from the phase 1/2 AG221-C-001 study showed that continued treatment with enasidenib resulted in improved survival and response times in patients with mutant-IDH2 relapsed or refractory (R/R) acute myeloid leukemia (AML).
Read Article

The results of the current phase 1b/2 study showed that the combination of azacitidine plus lirilumab was well-tolerated in heavily pretreated patients with relapsed acute myeloid leukemia (AML) and poor-risk disease features.
Read Article

An updated safety and efficacy analysis of a phase 1b study demonstrated a promising benefit–risk profile with the combination of the BCL-2 inhibitor venetoclax with either decitabine or azacitidine in elderly, treatment-naïve patients with acute myeloid leukemia (AML) who are not candidates for intensive standard induction therapy.
Read Article

The results of a post-hoc analysis of the RATIFY trial suggest that midostaurin decreases the cumulative incidence of relapse (CIR) in patients with FLT3 mutation–positive, newly diagnosed acute myeloid leukemia (AML), with no negative impact on survival.
Read Article

This analysis showed that ivosidenib-treated patients with IDH1-mutated (mIDH1), relapsed/refractory, and untreated acute myeloid leukemia (AML) whose best response is a complete remission (CR) or CR with partial hematologic recovery achieve mIDH1 clearance ≤0.04%.
Read Article

In this subanalysis of the AG221-C-001 phase 1 study, enasidenib monotherapy was found to be well-tolerated, and yielded hematologic responses in previously untreated older patients with IDH2-mutated (mIDH2) acute myeloid leukemia (AML) who are not fit to receive standard cytotoxic chemotherapy.
Read Article

The initial results of a phase 1 study suggest that combination therapy with ivosidenib or enasidenib plus standard induction chemotherapy is well-tolerated and effective in newly diagnosed patients with IDH-mutated (mIDH), relapsed/refractory acute myeloid leukemia (AML).
Read Article

In this analysis, the hedgehog pathway inhibitor sonidegib plus azacitidine combination therapy showed encouraging antileukemia activity in terms of high rate of disease stabilization, particularly in the relapsed/refractory acute myeloid leukemia patient population.
Read Article

Page 1 of 2